AXSM
$161.17
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Recent News
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference
Axsome Therapeutics (NASDAQ:AXSM) executives highlighted accelerating commercial momentum, a near-term regulatory catalyst, and a broad late-stage pipeline during a presentation at the Citizens JMP Life Sciences Conference. 2025 performance and near-term focus Chief Operating Officer Mark Jacobson
A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth
Axsome Therapeutics (AXSM) is back in focus after the FDA granted Priority Review to its AXS-05 program for Alzheimer's disease agitation, alongside reported 66% full-year 2025 net product revenue growth that is drawing fresh investor attention. See our latest analysis for Axsome Therapeutics. At a share price of $164.49, Axsome’s recent 13.27% 90 day share price return and 38.48% 1 year total shareholder return suggest momentum has picked up again after a softer year to date performance,...
2 Under-the-Radar Stocks to Buy and Hold
These biotechs are slowly making a name for themselves.
Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates
Axsome Therapeutics (NASDAQ:AXSM) executives provided updates on the company’s commercial portfolio and pipeline during a discussion hosted by Leerink Partners biopharma analyst Marc Goodman. Mark Jacobson, the company’s COO, and Nick Pizzie, CFO, outlined plans for the antidepressant Auvelity, the